United Capital Financial Advisers LLC reduced its stake in shares of Sanofi (NYSE:SNY) by 0.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,427 shares of the company’s stock after selling 205 shares during the period. United Capital Financial Advisers LLC’s holdings in Sanofi were worth $1,603,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of the stock. Menora Mivtachim Holdings LTD. bought a new stake in Sanofi during the fourth quarter valued at $109,000. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its stake in Sanofi by 6,188.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock valued at $171,000 after buying an additional 3,713 shares during the period. BLB&B Advisors LLC bought a new stake in Sanofi during the first quarter valued at $202,000. Huntington National Bank increased its stake in Sanofi by 3.4% in the first quarter. Huntington National Bank now owns 4,455 shares of the company’s stock valued at $202,000 after buying an additional 147 shares during the period. Finally, Lebenthal Asset Management LLC increased its stake in Sanofi by 322.5% in the fourth quarter. Lebenthal Asset Management LLC now owns 5,070 shares of the company’s stock valued at $205,000 after buying an additional 3,870 shares during the period. Hedge funds and other institutional investors own 9.86% of the company’s stock.
Shares of Sanofi (NYSE SNY) traded down 0.08% during trading on Friday, hitting $47.73. 1,511,331 shares of the company were exchanged. The company’s 50-day moving average price is $48.73 and its 200 day moving average price is $43.92. The stock has a market cap of $120.54 billion, a P/E ratio of 11.87 and a beta of 0.93. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.24.
Sanofi (NYSE:SNY) last released its quarterly earnings results on Friday, April 28th. The company reported $0.76 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.03. The business had revenue of $8.65 billion during the quarter, compared to analyst estimates of $8.40 billion. Sanofi had a net margin of 26.55% and a return on equity of 25.89%. Sanofi’s revenue was up 1.2% on a year-over-year basis. On average, equities analysts predict that Sanofi will post $3.15 earnings per share for the current fiscal year.
WARNING: “Sanofi (SNY) Shares Sold by United Capital Financial Advisers LLC” was first posted by sleekmoney and is owned by of sleekmoney. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://sleekmoney.com/sanofi-sny-shares-sold-by-united-capital-financial-advisers-llc/1915996.html.
Several equities analysts have commented on SNY shares. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a research note on Monday, April 24th. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $50.00 price target for the company in a research note on Tuesday, April 11th. Argus started coverage on shares of Sanofi in a research note on Thursday, April 6th. They issued a “buy” rating and a $50.00 price target for the company. Berenberg Bank downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Finally, Liberum Capital started coverage on shares of Sanofi in a research note on Thursday, March 9th. They issued a “hold” rating for the company. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the stock. Sanofi has an average rating of “Hold” and a consensus target price of $67.67.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/sanofi-sny-shares-sold-by-united-capital-financial-advisers-llc/1915996.html
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.